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Objective: To determine the frequency of pharmacogenomic variants and concurrent 
medications that may alter the efficacy and tolerability of acetylcholinesterase inhibitors 
(AChEIs).
Materials and methods: A multisite cross-sectional study was carried out across four memory 
care practices in the greater Indianapolis area. Participants were adults aged 65 years and older 
with a diagnosis of probable or possible Alzheimer’s disease (AD) (n=105). Blood samples and 
self-reported medication data were collected. Since two of the three AChEIs are metabolized by 
cytochrome P450 (CYP)-2D6, we determined the frequency of functional genetic variants in the 
CYP2D6 gene and calculated their predicted CYP2D6-activity scores. Concurrent medication 
data were collected from self-reported medication surveys, and their predicted effect on the 
pharmacokinetics of AChEIs was determined based on their known effects on CYP2D6 and 
CYP3A4/5 enzyme activities.
Results: Among the 105 subjects enrolled, 72% were female and 36% were African 
American. Subjects had a mean age of 79.6 years. The population used a mean of eight 
medications per day (prescription and nonprescription). The CYP2D6 activity score 
frequencies were 0 (3.8%), 0.5 (4.8%), 1.0 (36.2%), 1.5–2.0 (51.4%), and 2.0 (3.8%). 
Nineteen subjects (18.1%) used a medication considered a strong or moderate inhibitor 
of CYP2D6, and eight subjects (7.6%) used a medication considered a strong or moder-
ate inhibitor of CYP3A4/5. In total, 28.6% of the study population was predicted to have 
reduced activity of the CYP2D6 or CYP3A4/5 enzymes due to either genetic variants or 
concomitant medications.
Conclusion: Both pharmacogenetic variants and concurrent drug therapies that are predicted 
to alter the pharmacokinetics of AChEIs should be evaluated in older adults with AD. 
Pharmacogenetic and drug-interaction data may help personalize AD therapy and increase 
adherence by improving tolerability.
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Background
Acetylcholinesterase inhibitors (AChEIs) are the primary pharmacologic treatment 
for Alzheimer’s disease (AD). These medications do not alter the natural course of 
the disease, but they are believed to offer minor improvement in cognitive, functional, 
and behavioral symptoms associated with AD.1,2 Efficacy of the AChEIs may be 
modified by several factors, including stage of dementia, rate of cognitive decline, 
medication dose, and titration schedule.1,3 Adverse effects related to their procholinergic 
mechanisms often limit the tolerability of these medications, with nearly a third of 
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patients discontinuing treatment due to adverse effects such 
as nausea, vomiting, and diarrhea.1 Because of the marginal 
benefit and adverse effect profile, as many as 40% of AD 
patients discontinue treatment with AChEIs.4–6
Two factors that may contribute to the tolerability of 
AChEIs in AD patients are drug–drug interactions and phar-
macogenomics. Because of the frequent burden of chronic 
comorbid disease in the older adult population, many AD 
patients are routinely prescribed at least five medications, and 
consume additional over-the-counter medications.7,8 Many 
of these coadministered medications cause drug interactions 
either through altering the activities of the hepatic drug-
metabolizing enzymes9 or by pharmacodynamic properties 
suspected to limit the efficacy of AChEIs.10,11 Recent evidence 
highlights the mechanisms of drug interactions resulting from 
altered pharmacokinetics through hepatic metabolism.12 The 
specific enzymes involved in the metabolism of medications 
used in AD, specifically donepezil and galantamine, are 
cytochrome P450 (CYP) 2D6 and 3A4/3A5 (CYP3A4/5) 
enzymes.13,14 The metabolism of donepezil and galantamine 
may be influenced by either pharmacogenomic variants or 
comedications, and these variables may be used to identify 
those at higher risk of intolerable adverse effects.
Pharmacogenomic variants have been associated with 
altered pharmacokinetics of donepezil and galantamine.15–17 
Consequently, both comedications, as well as genetic varia-
tions in the drug-metabolizing enzymes, may be important 
factors contributing to the interindividual variability in the 
efficacy and tolerability of AChEIs. Prior literature has 
reported conflicting results when determining the relation-
ship between genetic variations and efficacy outcomes with 
AChEIs in AD;18–21 however, to our knowledge, no published 
data have described the influence of both pharmacogenomic 
variants or drug–drug interactions on efficacy or tolerability 
outcomes.15
Our objective in this study was to determine the frequency 
of pharmacogenomic variants and potential drug interac-
tions that may influence the pharmacokinetics of AChEIs, 
and ultimately efficacy and tolerability, in older adults with 
AD. Using CYP2D6 enzyme activity to guide dosing strat-
egies has been shown to improve tolerability with several 
medications, including antidepressants and antipsychotics.22 
Personalizing pharmacotherapy could be an approach to 
improve medication adherence by optimizing efficacy and 
improving tolerability profiles. We focused on the metabolic 
factors that are expected to alter medication exposure for 
donepezil and galantamine, since both are metabolized by 
hepatic CYP2D6 and CYP3A4/5 enzymes. We hypothesized 
that the presence of a high frequency of pharmacogenomic 
variants and drug interactions for AChEIs would support the 
need to pursue focused approaches to personalize pharma-
cotherapy and optimize efficacy-to-toxicity ratios for these 
vulnerable populations.
Materials and methods
Population and setting
The subjects included in this study were the first 105 subjects 
enrolled in a multisite randomized clinical trial (ClinicalTrials.
gov identifier: NCT01362686) to compare the tolerability of 
AChEIs in older adults with a diagnosis of AD.23 The study 
enrolled patients cared for in a memory care practice from one 
of four health care systems within the Indianapolis Discovery 
Network for Dementia.24 The study was approved by the insti-
tutional review boards for each health care system, including 
Indiana University–Purdue University of Indianapolis, the St 
Vincent Health System, and the Community Health Network. 
All enrolled participants provided informed consent through 
a legally authorized representative.
Eligible participants included those diagnosed with 
possible or probable AD for whom the provider was planning 
to initiate therapy with AChEIs. Inclusion criteria also 
required agreement from an informal caregiver to complete 
study-outcome assessments, access to a telephone, and the 
ability to understand English. Exclusion criteria consisted of 
current exposure to an AChEI or prior exposure that resulted 
in an adverse effect requiring drug discontinuation.
Medication-data collection
Medication data were collected by telephone interview 
through caregivers of study participants. Caregivers were 
asked to provide all medications the participant was taking 
at the time of the interview, including all prescription and 
over-the-counter medications. Medications were classified 
as prescription or over the counter by a clinical pharmacist 
(NLC) according to marketing status, as approved by the 
US Food and Drug Administration. Medications with CYP 
enzyme inhibitor or inducer status were identified using the 
Indiana University Department of Clinical Pharmacology 
drug-interaction table.9 This resource has been previously 
used to identify clinically relevant drug interactions and meta-
bolic pathways.25 Only medications identified as strong or 
moderate inhibitors were classified as enzyme inhibitors.
Additionally, medications were identified to have 
either possible or definite anticholinergic properties based 
on the Anticholinergic Cognitive Burden (ACB) scale.26 
Medications with anticholinergic properties block the action 
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of acetylcholine at muscarinic receptors, opposing the 
intended therapeutic effect of the AChEIs. Medications with 
possible anticholinergic effects were defined as those with 
serum anticholinergic activity or in vitro affinity to muscar-
inic receptors, but with no known clinically relevant negative 
cognitive effects (score of 1 on the ACB scale). Drugs with 
established and clinically relevant cognitive anticholinergic 
effects were considered definite anticholinergics (score of 
2 or 3 on the ACB scale). The ACB scale has been previously 
used to identify medications correlated with a higher risk of 
incident cognitive impairment.27,28
DnA extraction
Blood samples for genotyping were collected in 10 mL 
ethylenediaminetetraacetic acid Vacutainer tubes at the time 
of enrollment into the study. Deoxyribonucleic acid (DNA) 
was extracted from whole blood using the AutoGenFlex Star 
automated DNA extractor (AutoGen, Holliston, MA, USA) 
using the AGF FlexiGene and Blood DNA Finishing Kit 
(AutoGen) in the Indiana University sample-storage facility 
DNA-extraction service. Because polymorphic variants are 
infrequent in CYP3A4/5, we analyzed the CYP2D6 gene 
variants and not the CYP3A4/5 variants.
CYP2D6-genotyping and -activity scores
The CYP2D6 genotypes were determined for alleles 
CYP2D6*1, *2, *3, *4, *5, *6, *10, *17, *29, and *41 using 
TaqMan® assays.29 The genotyping results for each subject 
were converted to predicted CYP2D6-activity scores as previ-
ously described.30 Briefly, each subject’s activity score is the 
sum of the activities assigned to each of the subject’s two alleles. 
The wild-type full-activity alleles (*1, *2) were given a score 
of 1 each, the reduced function alleles (*10, *17, *29, *41) 
were given a score of 0.5, and the nonfunctional alleles (*3, 
*4, *5, *6) were given a score of 0. In the case of subjects 
with multiple copies (more than two), the multiple-copy allele 
was multiplied by two and then added to the second * allele. 
Therefore, the predicted CYP2D6-activity scores ranged 
from 0 to 3. If the subjects were taking a moderate CYP2D6 
inhibitor, their genetic score was multiplied by 0.5, and if 
they were taking a strong inhibitor, they were given a score 
of 0 to arrive at the predicted CYP2D6-activity score.
Analysis
We report descriptive results of the population for the pur-
poses of reporting frequencies of pharmacogenomic variants 
and drug interactions from concurrent medications that are 
expected to influence the AD drug pharmacokinetics in this 
population of older adults with AD. Continuous variables are 
presented as means and standard deviations, with categorical 
variables presented in percentages. Because our analysis 
was not focused on the number or type of comorbidities, 
but rather the number of concomitant medications used 
by study subjects, we report the number of prescription 
and over-the-counter medications as a surrogate marker of 
comorbidity.31
Results
The study population included the first 105 subjects enrolled 
in the clinical trial for whom we had both medication data 
and pharmacogenomic genotyping results available for 
analysis. The subjects were mostly female (72%), were 
mixed in educational level (28% with less than high school 
education), and had a diverse racial background (36% African 
Americans). The population used a mean of approximately 
eight medications per day, including both prescription and 
over-the-counter medications. Forty-four (41.9%) of the sub-
jects were taking at least nine concurrent medications. Only 
8% of subjects cared for in memory care practices used a 
medication with strong anticholinergic properties (Table 1).
Pharmacogenomic analysis revealed four subjects 
(3.8%) with a CYP2D6-activity score of 0, predicting poor 
metabolizer phenotypes with no CYP2D6 metabolic activ-
ity. Forty-three subjects (40.9%) had activity scores of 0.5 
or 1.0, predicting intermediate metabolizer phenotypes. 
Fifty-four subjects (51.4%) had activity scores of 1.5 or 
Table 1 Descriptive report of population characteristics and 
medications
Demographic variable Mean (SD)
Mean age, years 79.6 (9.1)
% Female 76 (72.4)
% African American 38 (36.2)
Education
% 12 years 29 (28.4)
% 12 years 31 (30.4)
% 12 years 42 (41.2)
Medication utilization
number of medications per subject 7.55 (4.10)
number of prescription medications per subject 5.36 (3.07)
number of OTC medications per subject 2.19 (2.03)
number with 0 medications 0
number (%) with 1–4 medications 26 (24.8)
number (%) with 5–8 medications 35 (33.3)
number (%) with 9–12 medications 31 (29.5)
number (%) with 12 medications 13 (12.4)
number (%) using any ACB drug 62 (59.0)
number (%) using ACB 2 or 3 8 (7.6)
Abbreviations: sD, standard deviation; OTC, over-the-counter; ACB, anticholinergic 
cognitive burden.
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2.0, predicting extensive metabolizers, and the remaining 
four subjects (3.8%) had activity scores greater than 2.0, 
predicting ultrarapid metabolizer phenotypes. The specific 
CYP2D6 allele frequencies and Hardy–Weinberg values are 
available in Table S1.
Results of the medication review showed that 19 subjects 
(18.1%) were using a medication considered a moderate 
or strong inhibitor of CYP2D6, and eight subjects (7.6%) 
were taking a medication considered a moderate inhibitor of 
CYP3A4/5. Eleven subjects (10.5%) were users of a moderate 
or strong inhibitor of CYP2D6 that reduced activity scores to 
poor metabolizer status (Table 2). The majority of the CYP2D6 
inhibitors used were sertraline and duloxetine, both considered 
moderate inhibitors of the CYP2D6 enzyme (Tables 2 and S2). 
The major inhibitor of CYP3A4/5 used by the study subjects was 
diltiazem, a moderate inhibitor of CYP3A4/5 (Tables 2 and S2). 
Additionally, 34.3% were using at least one CYP2D6 sub-
strate, and 59.0% were using at least one CYP3A4/5 substrate 
(Table S2).
Because hepatically metabolized AChEIs utilize both the 
CYP2D6 and CYP3A4/5 metabolic pathways, we quanti-
fied the number of subjects with reduced activity of either 
CYP2D6 or CYP3A4/5 due to either pharmacogenomic 
characteristics or concomitant medications acting as mod-
erate or strong enzyme inhibitors. Our results indicate that 
approximately 29% of our study population would have 
reduced activity of either CYP2D6 or CYP3A4/5 activity 
due to either pharmacogenomic variants or concomitant 
medications (Table 2). Two of the subjects (1.9%) were 
predicted to have reduced activity of both CYP2D6 and 
CYP3A4/5 (Table 2).
Discussion
Our study found that more than a quarter of our AD patients 
(~29%) were poor metabolizers of AChEIs, due to pharma-
cogenomic variants or the presence of drug–drug interactions. 
These findings may partially explain the high rate of adverse 
events limiting the chronic use of AChEIs. The population 
Table 2 Pharmacogenomic and drug-interaction results
Variable Frequency, n (%)
CYP2D6 activity scores
Predicted poor metabolizers
number with activity score 0
Predicted intermediate metabolizers
number with activity score 0.25–0.5
number with activity score 0.75–1.0a
Predicted extensive metabolizers
number with activity score 1.5 or 2.0
Predicted ultra-rapid metabolizers
number with activity score 2.0
Metabolic status: Pg only
4 (3.8)
5 (4.8)
38 (36.2)
54 (51.4)
4 (3.8)
Metabolic status: Pg + drug
7 (6.6)
8 (7.6)
43 (41.0)
43 (41.0)
4 (3.8)
Drug-interaction results
number using CYP2D6 inhibitor
Bupropionb
Duloxetinec
Paroxetineb
sertralinea
(one subject used both bupropion and duloxetine, thus sum of drugs is 20)
number using one or more CYP2D6 substrates
number using CYP3A4/5 inhibitor
Diltiazemd
Verapamild
number using one or more CYP3A4/5 substrates
19 (18.1%)
1
7
1
11
36 (34.3%)
8 (7.6%)
7
1
62 (59.0%)
Combination variables
number with reduced CYP2D6 activity
(activity score of 0–0.5 or using a CYP2D6 enzyme inhibitor)
number using a CYP3A4/5 enzyme inhibitor
number with reduced activity of either CYP2D6 or CYP3A4/5
number with reduced activity of CYP2D6 and CYP3A4/5
24 (22.9%)
8 (7.6%)
30 (28.6%)
2 (1.9%)
Notes: aFor some drugs, an activity score of 1.0 is considered an extensive metabolizer; bpotent CYP2D6 inhibitor; cmoderate CYP2D6 inhibitor; dmoderate CYP3A 
inhibitor.
Abbreviations: CYP, cytochrome P450; Pg, pharmacogenomic.
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included in this analysis represented a real-world sample of 
older adults enrolled from four health care systems, including 
a low-income safety-net health care system. The sample 
reflects a more normal distribution of educational status and 
racial diversity than what is commonly enrolled in AD studies 
conducted within purely academic medical centers and AD 
research centers. Therefore, the suggestion that both phar-
macogenomic characteristics and concomitant medications 
may contribute to differences in tolerability of AChEIs should 
apply to the majority of the US population with dementia. In 
our sample, the number of participants using a medication 
that reduced hepatic enzyme activity was two times higher 
than the number of subjects with pharmacogenomic causes 
for reduced enzyme activity.
Recent work in older adults with AD has shown conflict-
ing results on the association of pharmacogenomic charac-
teristics with clinical efficacy of AChEIs.20,21 The sources 
of variability in previously published literature are derived 
from different durations of treatment, definitions of efficacy 
outcomes, and populations with varying degrees of disease 
severity. The majority of the work associating pharmacog-
enomic characteristics with clinical outcomes in AD have 
focused on the efficacy of AChEIs, not tolerability.14,20,21 
Whether the activity of CYP2D6 enzymes has an impact 
on efficacy remains an important outcome to determine; 
however, we believe tolerability should also be pursued as 
an important clinical outcome. As stated in the Background 
section, a clinically significant number of patients prescribed 
AChEIs discontinue these medications, in part because of 
poor tolerability. Among those categorized as poor metabo-
lizers, and perhaps even intermediate metabolizers, higher 
serum concentrations of AChEIs may be more likely to 
induce an adverse effect than any therapeutic benefit of the 
medication. Whether clinical efficacy is improved with higher 
serum concentrations remains controversial, but improving 
tolerability may result in improved medication adherence 
and better efficacy outcomes.
Our findings that nearly 30% of older adults with AD 
may be poor metabolizers of two AChEIs should be validated 
with adverse-event data in clinical trials. We were not able 
to include clinical correlation with tolerability, because the 
clinical trial is ongoing and adverse events are a primary 
study outcome. Future studies and analyses from existing data 
sets should correlate pharmacogenomic and drug interactions 
with tolerability outcomes.
Our results suggest that if exposure definitions only consider 
pharmacogenomic characteristics, personalized approaches 
to the prescribing of AChEIs (specifically donepezil and 
galantamine) may be improved by genotyping hepatic enzyme 
activity in approximately one in 12 individuals to find those 
with reduced activity of the CYP2D6 enzyme (activity score 
0 or 0.5). However, considering the influence that both con-
comitant medications and pharmacogenomic characteristics 
may have on hepatic enzyme activity, nearly one in three older 
adults may benefit from a personalized approach to medication 
selection. Interestingly, the predominant influence on enzyme 
activity seen in our population was with the CYP2D6 enzyme, 
not the CYP3A4/5 enzyme, which has less influence on the 
metabolism of donepezil and galantamine.15,16
In our sample, 42% were using at least nine medications, 
and the risk of drug interactions is known to increase with the 
number of medications consumed,32 which further increases 
the risk of adverse events in this population. Only 8% used a 
medication with strong anticholinergic activity, a similar rate 
to that reported from other specialty care practices.33 Gardette 
et al found that concomitant use of anticholinergic agents 
increased the likelihood of discontinuation of AChEIs (hazard 
ratio 4.26, 95% CI 1.46–12.45).33 Although anticholinergics 
are known to cause a pharmacodynamic interaction, poten-
tially limiting efficacy, some commonly used anticholinergics 
are also CYP2D6 enzyme inhibitors (paroxetine, hydroxyzine, 
diphenhydramine) that may also increase the risk of adverse 
effects of those AChEIs metabolized through this pathway.9
Limitations to our findings include a small sample size 
and the collection of medication data using a caregiver report. 
Although our sample reflects more diversity than many 
prior studies in dementia, a larger sample size may improve 
generalizability. Among patients with dementia, assistance 
with medication adherence by a caregiver is recommended; 
therefore, using the caregiver report of medication utilization 
is a more appropriate resource for medication utilization 
than self-report. Although no gold standard exists for the 
evaluation of medication use, self-reporting and possibly 
caregiver reporting of medication use may overestimate 
actual medication-administration behavior.
It is unknown whether exposure to multiple medications 
that are substrates (not enzyme inhibitors) for the same 
enzyme would further modify the pharmacokinetics of 
AChEIs. In our study, 34% of participants were using a 
medication metabolized through the CYP2D6 pathway, and 
59% used a medication metabolized through the CYP3A4/5 
pathway. Future work should determine if the use of multiple 
substrates of CYP2D6 and CYP3A4/5 enzymes influences 
exposure to AChEIs.
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Conclusion
Our results indicate that both pharmacogenomic variants and 
concomitant medications may affect the pharmacokinetics 
and ultimately the efficacy and tolerability of AD medica-
tions. It will be important to determine the impact of these 
combined variables on clinical outcomes of tolerability 
and efficacy. Such findings should strengthen the rational 
approaches that can be used to personalize the pharmacologic 
management of older adults with AD.
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Table S1 Cytochrome P450-2D6 genotype frequencies and hardy–Weinberg (hW) test
*1 *2 *3 *4 *6 *10 *17 *29 *41
Major allele 9 38 105 77 104 72 99 95 91
heterozygote 49 38 0 24 1 28 6 10 12
Minor allele 47 29 0 4 0 5 0 0 2
hW P-value ◊ 0.01 1 0.39 1 0.45 1 1 0.20
Notes: ◊since the *1 allele is a default allele based on the lack of other alleles, the hardy–Weinberg test was not calculated, as the minor alleles are actually a variety of all 
other alleles tested.
Table S2 Medications with influence on hepatic enzymes used by study subjects
Enzyme inhibitor Enzyme inducer Enzyme substrate
CYP2D6 enzyme Bupropion (s)
Duloxetine (m)
Fluoxetine (s)
Paroxetine (s)
sertraline (m)
Carvedilol
Clonidine
Codeine
Metoprolol
nebivolol
Ondansetron
Oxycodone
Propafenone
Propranolol
risperidone
Tramadol
Venlafaxine
CYP3A4/5 enzyme Diltiazem (m)
Fluconazole (m)
Verapamil (m)
Modafanil Alprazolam
Amlodipine
Atorvastatin
Buspirone
Codeine
Diltiazem
eplerenone
Fentanyl
Finasteride
lovastatin
Methadone
nifedipine
Ondansetron
Propranolol
Quetiapine
risperidone
salmeterol
simvastatin
Trazodone
Zolpidem
Notes: Does not include study drug as enzyme substrate (acetylcholinesterase inhibitors). list includes only strong/moderate enzyme inhibitors, not weak inhibitors or 
inducers.
Abbreviations: CYP, cytochrome P450; s, strong; m, moderate.
